{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:19Z","timestamp":1787026939013,"version":"build-2736575974"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00001","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T08:58:50Z","timestamp":1580461130000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":96,"title":["Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma"],"prefix":"10.3389","volume":"10","author":[{"given":"Stefania","family":"Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Larocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.seminhematol.2018.03.001","article-title":"MRD testing in multiple myeloma: the main future driver for modern tailored treatment","volume":"55","author":"Landgren","year":"2018","journal-title":"Semin Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"B5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/cyto.a.22581","article-title":"Quality assessment program for euroflow protocols: summary results of four-year (2010-2013) quality assurance rounds","volume":"87","author":"Kalina","year":"2015","journal-title":"Cytom Part A"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/cncr.31854","article-title":"Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis","volume":"125","author":"Gambella","year":"2019","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bbmt.2011.07.002","article-title":"The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter","volume":"18","author":"Korthals","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.09.005","article-title":"Concordance of post-consolidation minimal residual disease rates by multiparametric flow cytometry and next-generation sequencing in CASSIOPEIA","volume-title":"17th International Myeloma Workshop Abstract Book","author":"Avet-Loiseau","year":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2017.58","article-title":"Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma","volume":"31","author":"Martinez-Lopez","year":"2017","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging \u201cearly myeloma","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1365-2141.2011.08658.x","article-title":"Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology","volume":"153","author":"Hillengass","year":"2011","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1182\/blood-2011-09-379818","article-title":"PET-CT in MM: a new definition of CR","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3324\/haematol.2012.065359","article-title":"Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma","volume":"97","author":"Hillengass","year":"2012","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/bjh.12007","article-title":"The role of imaging techniques in the management of multiple myeloma","volume":"159","author":"Zamagni","year":"2012","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminhematol.2018.02.001","article-title":"Minimal residual disease in multiple myeloma: use of magnetic resonance imaging","volume":"55","author":"Hillengass","year":"2018","journal-title":"Semin Hematol"},{"key":"B26","first-page":"479","article-title":"Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: A new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V130.SUPPL_1.905.905","article-title":"Impact of next-generation flow (NGF) Minimal Residual Disease (MRD) monitoring in multiple myeloma (MM): results from the Pethema\/GEM2012 trial","volume":"130","author":"Paiva","year":"2017","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG\u2013positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.7150\/thno.20491","article-title":"11C-methionine-PET in multiple myeloma: a combined study from two different institutions","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fmed.2019.00069","article-title":"Interest of pet imaging in multiple myeloma","volume":"6","author":"Jamet","year":"2019","journal-title":"Front Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research council myeloma IX study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","article-title":"Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.245.245","article-title":"Impact of minimal residual disease in transplant ineligible myeloma patients: results from the UK NCRI myeloma XI trial","volume":"128","author":"de Tute","year":"2016","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/bjh.13582","article-title":"Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up","volume":"171","author":"Ludwig","year":"2015","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","article-title":"Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma","volume":"29","author":"Paiva","year":"2011","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lo","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/leu.2014.219","article-title":"Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival","volume":"29","author":"Ferrero","year":"2015","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1016\/j.bbmt.2018.07.040","article-title":"Longitudinal flow cytometry identified \u201cminimal residual disease\u201d (MRD) evolution patterns for predicting the prognosis of patients with transplant-eligible multiple myeloma","volume":"24","author":"Gu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4409.4409","article-title":"Prognostic impact of minimal residual disease by ASO-RQ-PCR in multiple myeloma: a pooled analysis of 2 phase III studies in patients treated with lenalidomide after front-line therapy","volume":"128","author":"Oliva","year":"2016","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.8011","article-title":"Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: results from the EMN02\/HO95 phase 3 trial","volume":"35","author":"Oliva","year":"2017","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-151","article-title":"Efficacy and updated safety analysis of a safety run-in cohort from griffin, a phase 2 randomized study of daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple M","volume":"132","author":"Voorhees","year":"2018","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the forte trial","volume":"37","author":"Gay","year":"2019","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.bbmt.2018.12.687","article-title":"Minimal residual disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM): results of the prognostic immunophenotyping for myeloma response (PRIMeR) study","volume":"25","author":"Hahn","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111244","article-title":"Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant","volume":"132","author":"Ocio","year":"2018","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.675.675","article-title":"Final results of a phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM)","volume":"128","author":"Zimmerman","year":"2016","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8017","article-title":"Efficacy of daratumumab. (DARA) + bortezomib\/thalidomide\/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: analysis of the CASSIOPEIA trial","volume":"37","author":"Avet-Loiseau","year":"2019","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","article-title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation","volume":"28","author":"Takamatsu","year":"2017","journal-title":"Ann Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"B60","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/01.HS9.0000561764.53887.c0","article-title":"Curative strategy (gem-cesar) for high-risk smoldering myeloma: carfilzomib, lenalidomide and dexamethasone (krd) as induction followed by hdt-asct, consolidation with krd and maintenance with rd","volume":"3","author":"Mateos","year":"2019","journal-title":"HemaSphere"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acg2.71","article-title":"Minimal residual disease in multiple myeloma 2019","author":"Kunacheewa","year":"2019","journal-title":"Adv Cell Gene Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.191.191","article-title":"Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM\/DFCI 2009 trial","volume":"126","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2018.09.008","article-title":"Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: a pooled analysis of 2 phase III trials","volume":"132","author":"D'Agostino","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B66","unstructured":"FDA Authorizes First Next Generation Sequencing-Based Test to Detect Very Low Levels of Remaining Cancer Cells in Patients With Acute Lymphoblastic Leukemia or Multiple Myeloma2018"},{"key":"B67","unstructured":"2016"},{"key":"B68","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(19)31711-8","article-title":"Surrogate endpoints in randomised controlled trials: a reality check","volume":"394","author":"Kumar","year":"2019","journal-title":"Lancet."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.1038\/bcj.2017.14","article-title":"Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: impact on the revised IMWG diagnostic criteria of multiple myeloma","volume":"7","author":"Lee","year":"2017","journal-title":"Blood Cancer J"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv"},{"key":"B71","first-page":"243","article-title":"Single-cell analysis of circulating tumor cells","volume-title":"Methods in Molecular Biology","author":"Thiele","year":""},{"key":"B72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1053\/j.seminhematol.2018.02.008","article-title":"Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease","volume":"55","author":"Thoren","year":"2018","journal-title":"Semin Hematol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1373\/clinchem.2015.242651","article-title":"Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration","volume":"62","author":"Bergen","year":"2016","journal-title":"Clin Chem"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.1038\/bcj.2017.75","article-title":"High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma","volume":"7","author":"Mills","year":"2017","journal-title":"Blood Cancer J"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T08:58:55Z","timestamp":1580461135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":74,"alternative-id":["10.3389\/fonc.2020.00001"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00001","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"article-number":"1"}}